Capital World Investors Cuts ALNY Stake to 13.5%

TL;DR

**Capital World Investors just trimmed their ALNY stake to 13.5%.**

AI Summary

Capital World Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing a decrease in its beneficial ownership of Alnylam Pharmaceuticals, Inc. (ALNY) common stock. As of December 29, 2023, Capital World Investors now beneficially owns 16,350,708 shares, representing 13.5% of Alnylam's outstanding common stock. This is a notable reduction from their previous reported stake, indicating a potential shift in their investment strategy for ALNY.

Why It Matters

This filing shows a significant institutional investor has reduced its position in Alnylam, which could signal a change in their outlook on the company's future performance or valuation.

Risk Assessment

Risk Level: medium — A large institutional investor reducing its stake can sometimes precede further selling pressure or reflect concerns about the company's prospects.

Analyst Insight

Investors should monitor Alnylam's stock for potential increased selling pressure and consider if this reduction by a major investor aligns with their own investment thesis for the company.

Key Numbers

• 16,350,708 — Shares Beneficially Owned (This is the total number of shares Capital World Investors now holds in Alnylam.)
• 13.5% — Percentage of Class (This represents the proportion of Alnylam's common stock owned by Capital World Investors, indicating a reduced stake.)

Key Players & Entities

• Capital World Investors (company) — the reporting person decreasing its ownership
• Alnylam Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
• 16,350,708 (dollar_amount) — number of shares beneficially owned by Capital World Investors
• 13.5% (dollar_amount) — percentage of Alnylam's common stock beneficially owned by Capital World Investors
• December 29, 2023 (date) — the date of the event requiring the filing

Forward-Looking Statements

• Alnylam's stock price may experience short-term volatility due to the reduced institutional ownership. (ALNY) — medium confidence, target: Q1 2024

FAQ

Filing Documents

• SEC13G_Filing.htm (SC 13G/A) — 16KB
• 0001422848-24-000213.txt ( ) — 18KB

From the Filing

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 ) * Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 02043Q107 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital World Investors 95-1411037 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 16,350,708 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 16,398,889 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 16,398,889 Beneficial ownership disclaimed pursuant to Rule 13d-4 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.1% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Alnylam Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices 675 West Kendall Street, HENRI A. TERMEER SQUARE, Cambridge, MA 02142 Item 2. (a) Name of Person Filing Capital World Investors (b) Address of Principal Business Office or, if None, Residence 333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071 (c) Citizenship N/A (d) Title of Class of Securities Common Stock (e) CUSIP Number 02043Q107 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J). Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 16,398,889 ** (b) Percent of Class: 13.1% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 16,350,708 (ii) shared power to vote or to direct the vote 0 (iii) sole power to dispose or to direct the disposition of 16,398,889 (iv) shared power to dispose or to direct the disposition of 0 **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 16,398,889 shares or 13.1% of the 125,492,927 shares believed to be outstanding. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to b

View Full Filing

View this SC 13G/A filing on SEC EDGAR